Novo Nordisk Cleared to Acquire Three Catalent Manufacturing Sites for $CTLT Following FTC Approval

Dec 14, 2024, 08:49 AM

Novo Nordisk has received clearance to proceed with its acquisition of three manufacturing sites from Catalent, following the Federal Trade Commission's decision not to challenge the deal. This acquisition is part of a larger transaction involving Catalent and Novo Holdings, which has also met all regulatory closing conditions. The approval allows Novo Nordisk to enhance its manufacturing capabilities by integrating these sites, thereby strengthening its position in the pharmaceutical sector. The deal has been noted as significant given the current regulatory environment surrounding pharmaceutical acquisitions.